CROMA-PHARMA
31.5.2021 17:12:04 CEST | Business Wire | Press release
Croma-Pharma (Croma) is opening a new chapter and expanding its product portfolio to meet the growing needs of its customers. With the innovative skincare brand Croma farewell™, the company is specifically addressing the desire of consumers for natural, effective and individual skincare and building upon its many years of experience in the production of hyaluronic acid. The name says it all: consumers say goodbye to their facial skin problems and hello to their new selves when using Croma farewell™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210531005179/en/
The Austrian produced brand will initially launch in all key markets with facial serums for five specific skin types.
High-quality care for specific skin conditions based on hyaluronic acid
Genetics, external factors and psychological influences can have a decisive impact on an individual’s skin condition and lead to various problems. Croma viewed this situation as an opportunity to develop a high-quality facial care line for specific skin needs: Croma farewell™.
The Croma farewell™ cosmetic portfolio of five different facial serums unites carefully selected ingredients with years of experience in the pharmaceutical and aesthetic field. Based on this expertise, all formulations contain a blend of both high and low molecular weight hyaluronic acid – an antioxidant that moisturizes and hydrates the skin, improves elasticity and smoothes and plumps the skin’s appearance to reduce fine lines and wrinkles.
All ingredients incorporated into the serums are carefully selected and based on scientific data to achieve the most effective results.
"With the launch of Croma farewell™, we are strengthening our focus on personalized skincare innovation, drawing on our many years of expertise as well as the latest scientific findings. Croma farewell™ meets the high standard of our medical products and perfectly complements our existing portfolio", explains Managing Director, Andreas Prinz.
Concentrated efficacy: 5 serums for 5 common facial skin conditions
-
farewell irritated skin: Target-specific face serum for irritated, sensitive skin with Hyaluronic Acid, Madecassoside, Niacinamide and D-Panthenol to sooth irritations, reduce skin redness and strengthen the skin barrier.
Perfume free. 30 ml.
-
farewell puffy eyes: A face serum, especially designed for the eye contour, to fight the appearances of puffiness, dark circles and crow's feet. The diligent formulation contains Hyaluronic Acid, D-Panthenol and a complex of Ash tree bark extract, organic silicon and Vitamin B3 for radiant, glowing skin and a fresher look.
Perfume free. 30 ml.
-
farewell dry skin: farewell dry skin contains hydrating ingredients including Hyaluronic Acid, Niacinamide, D-Panthenol and Aloe Vera to effectively nourish the skin and strengthen the skin barrier. Softens the skin and boosts elasticity.
Perfume free. 30 ml.
-
farewell aging skin: farewell aging skin is enriched with Hyaluronic Acid, Madecassoside, Vitamin C, Marine ferment extract and a plant-derived Retinol alternative to hydrate the skin and improve suppleness and firmness while effectively reducing the signs of aging.
Perfume free. 30 ml.
-
farewell oily skin: Formulated especially for oily and acne-prone skin, farewell oily skin contains a zinc complex and plankton extract to reduce blemishes and clogged pores, while diminishing the facial sebum production. Niacinamide and Wintergreen leaf extract regenerate the skin barrier for a softer skin and a glowing complexion.
Perfume free. 30 ml.
farewell follows clean beauty concept
More and more people attach great importance to responsible consumption. Croma farewell™ complies with this wish – all serums are vegan, free from silicones, perfumes, mineral oils and are developed and produced exclusively in Austria. The products are cruelty-free and contain no animal-derived ingredients.
Price and availability
The Croma farewell™ facial serums are available soon via the Croma skincare web shop www.cromaskincareshop.com
and selected partners.
Recommended retail price: EUR 119,-.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005179/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom